How big is the growth hormone deficiency market today, and what are its future growth expectations?
The growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of strategic initiatives, increasing incidences of brain tumors, growing demand for hormone therapies, increased elderly population, and rising government funding for healthcare.
The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the growing prevalence of genetic disorders, rising number of strategic initiatives, increased research and development, increasing morbidity of Gh disease, and rising number of clinical trials. Major trends in the forecast period include technological advancement, expanding treatment options, advancements in diagnostic techniques, new recent developments, and advancements in biotechnology.
Get Your Free Sample of The Global Growth Hormone Deficiency Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21197&type=smp
What have been the primary factors driving the growth hormone deficiency market’s growth?
The growing prevalence of genetic disorders is expected to propel the growth of the growth hormone deficiency market going forward. Genetic disorders refer to medical conditions caused by abnormalities or mutations in an individual’s DNA, either inherited or occurring spontaneously. The prevalence of genetic disorders is due to advancements in diagnostic technology, increased awareness, rising maternal age, environmental factors causing mutations, population growth, and improved survival rates for affected individuals. Growth hormone deficiency is used to manage growth-related complications in certain genetic conditions. For instance, in December 2022, according to a report published by the Department of Health & Social Care (DHSC), a UK-based government department, in October 2022, around 33,000 whole genome equivalents were sequenced, with an average diagnostic yield of 32%, rising to 61% in specific conditions. Therefore, the growing prevalence of genetic disorders drives the growth of the growth hormone deficiency market.
What are the key segments within the growth hormone deficiency market?
The growth hormone deficiency market covered in this report is segmented –
1) By Type: Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency
2) By Treatment: Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, Surgery
3) By Route Of Administration: Intravenous, Intramuscular, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency, Genetic Growth Hormone Deficiency, Acquired Growth Hormone Deficiency
2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency, Secondary Growth Hormone Deficiency
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/growth-hormone-deficiency-global-market-report
Which key players are shaping the growth hormone deficiency market?
Major companies operating in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.
How will emerging trends drive the growth hormone deficiency market throughout the forecast period?
Major companies operating in the growth hormone deficiency market are focusing on developing innovative products, such as unmodified somatropin, for daily pediatric growth hormone deficiency (GHD) treatments. Unmodified somatropin refers to the same growth hormone used in daily pediatric growth hormone deficiency treatments but delivered in a once-weekly dosage with Skytrofa. For instance, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched the SKYTROFA (lonapegsomatropin) for the once-weekly treatment of pediatric growth hormone deficiency (GHD). This innovative therapy offers enhanced convenience, improved adherence, and potentially better treatment outcomes than traditional daily growth hormone therapies. It is the first and only FDA-approved once-weekly treatment for pediatric GHD, positioning it as a groundbreaking advancement in endocrinology and pediatric care.
How do regional factors impact the growth hormone deficiency market, and which region is the largest contributor?
North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Growth Hormone Deficiency Market Report 2025 Offer?
The growth hormone deficiency market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21197
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
